Incyte to Acquire Villaris Therapeutics and Auremolimab (VM6)
October 3, 2022
Incyte has entered into an agreement to acquire Villaris Therapeutics, a Medicxi-backed biopharmaceutical focused on vitiligo. Incyte will pay $70 million upfront and provide potential additional milestone payments of up to $1.36 billion for auremolimab (VM6), an anti-IL-15Rβ monoclonal antibody.
- Buyers
- Incyte
- Targets
- Villaris Therapeutics, Auremolimab (VM6)
- Industry
- Pharmaceuticals
- Location
- North Carolina, United States
- Transaction Type
- Buyout
Explore More
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.